Amgen (AMGN) Tops Q2 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amgen (AMGN) PT Raised to $179 at Baird
July 27, 2018 8:48 AM EDTBaird raised its price target on Amgen (NASDAQ: AMGN) to $179.00 (from $165.00) while maintaining a Neutral rating.
... MoreAmgen (AMGN) PT Raised to $205 at Cowen Following 'Beat and Raise'
July 27, 2018 8:24 AM EDTCowen raised its price target on Amgen (NASDAQ: AMGN) to $205.00 (from $204.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Amgen reported Q2 revenue of $6.06B (+4% Y/Y, vs. consensus of $5.73BE) and non-GAAP EPS of $3.83 (+17% Y/Y, vs. consensus of $3.54E). Amgen both... More
Amgen (AMGN) PT Raised to $194 at UBS
July 27, 2018 7:00 AM EDTUBS raised its price target on Amgen (NASDAQ: AMGN) to $194.00 (from $180.00) while maintaining a Neutral rating.
... MoreAmgen (AMGN) PT Raised to $195 at Barclays
July 27, 2018 6:56 AM EDTBarclays raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Equalweight rating following the company's 2Q earnings report.
Amgens portfolio looks poised to deliver flat growth in 2018e, which, in Barclays view, will likely keep... More
Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q
July 27, 2018 6:45 AM EDTPiper Jaffray raised its price target on Amgen (NASDAQ: AMGN) to $210.00 (from $190.00) while maintaining a Overweight rating following the company's 2Q earnings report. AMGN posted Q218 non-GAAP EPS of $3.83, well ahead of consensus $3.55. Upside was operationally driven as revenue beat handily (total revenue was... More
